A patient with esophageal squamous cell carcinoma who had a complete pathological response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil
β Scribed by Takashi Ui; Michitaka Nagase; Yoshinori Hosoya; Kentaro Kurashina; Hidenori Haruta; Toru Zuiki; Yoshikazu Yasuda; Takashi Ura; Kei Muro; Hirofumi Fujii
- Publisher
- Springer
- Year
- 2011
- Tongue
- English
- Weight
- 270 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1612-9059
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A Phase II trial was initiated to evaluate the response to and toxicity of a new regimen of weekly outpatient neoadjuvant chemotherapy in patients with oral carcinoma. ## METHODS. Patients with previously untreated squamous cell carcinoma of the oral cavity were eligible for this trial. The neoad
## Abstract ## BACKGROUND The authors conducted a series of four Phase IβII trials of highβdose and intermediateβdose docetaxel, cisplatin, and 5βfluorouracil (TPF)βbased induction chemotherapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). The chemotherapy regime
## Abstract ## Background. The role of adjuvant neck dissection in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) who obtain complete clinical and radiologic response following definitive chemoradiation treatment is controversial. ## Methods. Patterns of fail